Pharsight

Giapreza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9867863 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(5 years from now)

US10548943 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(5 years from now)

US10500247 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(5 years from now)

US10335451 LA JOLLA PHARMA Method of treating low blood pressure
Dec, 2029

(5 years from now)

US9572856 LA JOLLA PHARMA Method of treating low blood pressure
Jul, 2031

(7 years from now)

US9220745 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US10028995 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US10493124 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US11559559 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US11096983 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(10 years from now)

US11219662 LA JOLLA PHARMA Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II
Jan, 2037

(12 years from now)

Giapreza is owned by La Jolla Pharma.

Giapreza contains Angiotensin Ii Acetate.

Giapreza has a total of 11 drug patents out of which 0 drug patents have expired.

Giapreza was authorised for market use on 23 December, 2021.

Giapreza is available in solution;intravenous dosage forms.

Giapreza can be used as treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor, treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock, treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use, treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above, treating distributive shock with angiotensin ii, increasing blood pressure with an initial rate of about 20 ng/kg/min angiotensin ii in a human subject having septic shock, and titrating the rate up., treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension, increasing blood pressure in a patient having distributive shock, maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use, treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor, treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor.

Drug patent challenges can be filed against Giapreza from 21 December, 2021.

The generics of Giapreza are possible to be released after 06 January, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 21, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date:

21 December, 2021

Market Authorisation Date:

23 December, 2021

Treatment:

Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Increasing blood pressure with an initial rate of about 20 ng/kg/min ang...

Dosage:

SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before its drug patent expiration?

More Information on Dosage

GIAPREZA family patents

Family Patents